

Press Release

Cathay Securities Investment Trust Launches Cathay Global Genomics Immunology and Medical Revolution ETF - First Taiwanese ETF Tracking a Solactive Index

22 November 2021

FRANKFURT AM MAIN – In the wake of its massive negative impacts, the pandemic has accelerated the development of new pharmaceuticals and vaccines. For example, mRNA-based pharmaceuticals, whose technology originated in the late 60s of the previous century, finally reached approval status, and its potential usage far exceeds its current application as an effective vaccine against SARS-COVID-19.¹ Cathay Securities Investment Trust, one of the largest Taiwanese asset managers, now launched an ETF tracking companies pioneering in the development of innovative medication. The ETF, the Cathay Global Genomics Immunology and Medical Revolution ETF (Stock Code: 00898), started trading on Taiwan Stock Exchange on 22nd November 2021, with IPO listing assets of c.130mn USD. The ETF tracks the Solactive Global Genomics Immunology and Medical Revolution Index (SOLGIMRN).

According to a recent study, genomics technology holds the potential to generate revenues of USD 54.4 billion by 2025 from USD 22.7 billion in 2020, growing at a CAGR of 19.0% during the forecast period². This market expectation implies the tremendous potential that this cutting-edge technology cocoons, and as a sideline, denotes the capability it holds to revolutionize not only the entire biotechnology sector, but also the way humanity treats illnesses. The **Solactive Global Genomics Immunology and Medical Revolution Index** serves as a representation of companies that have business operations in the biotechnology and genomics industry.

Companies that are eligible for index inclusion must be classified as, for example, Pharmaceuticals, Biotechnology, Medical Specialties, or Managed Health Care, according to conventional Industries and Economic Sectors classification systems. If a company qualifies in this context, Solactive executes a greater in-depth analysis to reveal the candidate's relevance to the respective theme. To derive a company's significance, Solactive's proprietary **ARTIS**[®] engine screens publicly available information such as financial websites, regulatory filings, or company publications using its natural language processing algorithm.

¹ <https://www.nature.com/articles/d41586-021-02483-w>

² <https://www.marketsandmarkets.com/Market-Reports/genomics-market-613.html>

Solactive AG
German Index Engineering
Platz der Einheit 1
60327 Frankfurt am Main
Germany

Steffen Scheuble
CEO
+49 (69) 719 160-20
steffen.scheuble@solactive.com

Michael Li Ming Nuske, CFA
Sales Manager APAC
+852 3905 3101
michael.nuske@solactive.com

Phil Wiedbrauck
PR & Communications
+49 (69) 719 160-311
phil.wiedbrauck@solactive.com

"The pandemic has put global medical sectors into the spotlight, and many pharmaceutical revolutions originated in the previous 18 months with genomics technology and personalized medicine being part of a much broader and auspicious trend," comments Timo Pfeifer, Chief Markets Officer at Solactive. *"With major player Cathay, we are very honored to expand our APAC footprint to Taiwan, and we are looking forward to establishing a longstanding business relationship with them, developing more innovative products together in the future."*

"In the past two years, we've seen the importance of medical investment, and we believe health is the biggest wealth for everyone. Thus, we're so honored to cooperate with the German thematic index expert Solactive to bring Cathay Genomics Immunology and Medical Revolution ETF to Taiwan market to provide investors an indispensable vehicle to their portfolio that invest in companies with revolutionary medical technologies. As the biggest asset management company in Taiwan, it's always important to have partners like Solactive to offer better opportunities to our investors and to keep our leading position," said Eddie Cheng, Head of Quantitative and Index Business Division.

For more information please visit: <http://www.solactive.com>

Solactive AG
German Index Engineering
Platz der Einheit 1
60327 Frankfurt am Main
Germany

Steffen Scheuble
CEO
+49 (69) 719 160-20
steffen.scheuble@solactive.com

Michael Li Ming Nuske, CFA
Sales Manager APAC
+852 3905 3101
michael.nuske@solactive.com

Phil Wiedbrauck
PR & Communications
+49 (69) 719 160-311
phil.wiedbrauck@solactive.com

Note to editors

About Solactive

Solactive is a leading provider of indexing, benchmarking, and calculation solutions for the global investment and trading community. Headquartered in Frankfurt, and, with offices in Hong Kong, Toronto, Berlin, and Dresden, we innovate and disrupt the status quo as the partner of choice for our clients.

The unique blend of our 250 staff's expertise in data, data science, financial markets, and technology enables our clients' continued success through the delivery of a superior experience, unique customization capabilities, and the best value for money available in the industry. With more than 18,000 indices calculated daily, we offer a full suite of solutions, including market-leading ESG and thematic indices.

As at April 2020, Solactive served approximately 450 clients across the world, with approximately US\$200 billion invested in products linked to our indices. Solactive is registered with ESMA as a benchmark administrator and is supervised by the BaFin.

Disclaimer

The information in this document does not constitute tax, legal or investment advice and is not intended as a recommendation for buying or selling securities. Solactive AG and all other companies mentioned in this document are not responsible for the consequences of reliance upon any opinion or statement contained herein or for any omission.

Solactive AG, Platz der Einheit 1, 60327 Frankfurt am Main, Germany. Registered Office: Frankfurt am Main, Registration Court: Amtsgericht Frankfurt am Main, HRB: 79986, USt-IdNr.: DE 255 598 976. Management Board: Steffen Scheuble, Christian Vollmuth, Alexander Steiner, and Timo Pfeiffer, Head of Supervisory Board: Dr Felix Mühlhäuser.

Solactive AG
German Index Engineering
Platz der Einheit 1
60327 Frankfurt am Main
Germany

Steffen Scheuble
CEO
+49 (69) 719 160-20
steffen.scheuble@solactive.com

Michael Li Ming Nuske, CFA
Sales Manager APAC
+852 3905 3101
michael.nuske@solactive.com

Phil Wiedbrauck
PR & Communications
+49 (69) 719 160-311
phil.wiedbrauck@solactive.com